University of California

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
AbbVie, Internal medicine, Onyx Pharmaceuticals, Immunotherapy, Hematology, Science, University, Biology, MBA, University of California, Therapy, Division, Eli Lilly and Company, CMO, University of Southern California, Pharmaceutical industry

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors.

Key Points: 
  • BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors.
  • Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board.
  • She currently serves on the Board of Directors of Nurix Therapeutics, Inc., ORIC Pharmaceuticals, Inc., and K36 Therapeutics, Inc. She is also a scientific advisor to several clinical-stage oncology and immunotherapy companies.
  • “I am honored to transition from my role as a scientific advisor to a member of the Board of Directors,” said Dr. Kunkel.

Brain & Behavior Research Foundation Awards Distinguished Investigator Grants Valued at $1 Million to 10 Scientists Pursuing Innovative Mental Health Research

Retrieved on: 
Thursday, April 4, 2024
Depression, Patient, Mitochondrion, Doctor of Science, Harvard University, Therapy, Research, Risk, Mental health, University of Pittsburgh, Brain, DSM-IV codes, Brown University, Cannabis, Memory, Safety, Spectrum, Mitophagy, Schizophrenia, Hippocampus, Bipolar disorder, Anxiety, Learning, University, Psychopathology, Cerebrospinal fluid, University of California, Distinguishing, PET, Biomarker, Hope, Baylor College of Medicine, Behavior, AMPA, Fragile X syndrome, PTSD, Pharmaceutical industry

New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.

Key Points: 
  • New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.
  • By funding transformative research focused on new ways to prevent, diagnose, and treat psychiatric disorders, our Distinguished Investigator Grants are encouraging established scientists to continue advancing our understanding of mental illness and disorders of brain and behavior,” says Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation.
  • The ground-breaking work of the Distinguished Investigator Grant recipients will bring hope and healing to people and families impacted by mental illness.
  • We applaud these scientists for their extraordinary dedication, innovation, and leadership.”
    Recipients of the Distinguished Investigator Grants are full professors at research institutions in the United States and abroad.

Urology Care Foundation Announces 2024 Research Awards of Distinction

Retrieved on: 
Thursday, April 4, 2024
Western University, Research, American Urological Association, Xenobiotic, Translational research, Postdoctoral researcher, Prostate cancer, Environment, Lawson Health Research Institute, Immunology, Committee, Gut microbiota, University, Macrophage, Doctor of Philosophy, Role, Publication, Pediatrics, University of California, Pediatric urology, Division, FACS, Radiation therapy, Society, Michigan Medicine, Nursing

BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.

Key Points: 
  • BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.
  • "We are optimistic about the future of urologic research with the selection of the recipients of this year’s Urology Care Foundation Research Awards,” said Harris M. Nagler, MD, Urology Care Foundation President.
  • “We are thrilled with the Urology Care Foundation Research Awards of Distinction awardees this year,” said Steven Kaplan, MD, Chair of the AUA’s Research Council.
  • The awardees will be celebrated at the Urology Care Foundation Research Honors Program held at the AUA Annual Meeting in May 2024.

American Shared Hospital Services Pays Tribute to Ernest A. Bates, M.D., Founder and Former Chairman and CEO

Retrieved on: 
Tuesday, March 26, 2024
MRI, Radiosurgery, UCSF, Jacobi Medical Center, ASHS, Executive, Trustee, SAN, Black, University, MD, Medical Center, Dentistry, University of California, Johns Hopkins University, AMS, M.D

Ray Stachowiak, Executive Chairman of American Shared Hospital Services, remembers Dr. Bates fondly, stating, “We want to thank him for his profound contributions to the Company and to many people, including me, personally, for the past 35 years.

Key Points: 
  • Ray Stachowiak, Executive Chairman of American Shared Hospital Services, remembers Dr. Bates fondly, stating, “We want to thank him for his profound contributions to the Company and to many people, including me, personally, for the past 35 years.
  • He expanded accessibility to centers throughout the U.S. and in South America, building a solid foundation for American Shared Hospital Services’ future success.
  • Known for his intellectual curiosity, generous philanthropy, and longstanding service and dedication to American Shared Hospital Services, Dr. Bates was widely known in the healthcare industry and forged long-term friendships throughout his lifetime.
  • He previously provided consulting services to the Company pursuant to a consulting agreement from December 2021 through March 2022 before rejoining the Board in March 2022.

Trilogy Real Estate Group Hires Erica Blue as Product Specialist and Assistant Territory Manager

Retrieved on: 
Tuesday, April 9, 2024
Blue, Georgetown University, University, Trauma surgery, University of California, Trilogy, Investment, CAIA, FINRA, Capital Square

CHICAGO, April 9, 2024 /PRNewswire/ -- Trilogy Real Estate Group , a Chicago-based real estate investment and property management firm, announced today that Erica Blue has joined the company as product specialist and assistant territory manager.

Key Points: 
  • CHICAGO, April 9, 2024 /PRNewswire/ -- Trilogy Real Estate Group , a Chicago-based real estate investment and property management firm, announced today that Erica Blue has joined the company as product specialist and assistant territory manager.
  • "We are building a top-tier sales team to support our growing investment platform and are pleased that Erica has joined forces with us," said Matt Leiter, chief financial officer for Trilogy Real Estate Group.
  • "Erica has an impressive track record and a passion for real estate that make her ideally suited for this opportunity."
  • Trilogy Real Estate Group acquires, develops and manages properties across the Midwest and the Southeast, and has sponsored more than 16 investment offerings, including DSTs and qualified opportunity zone funds.

Dairy Council of California Announces 2024 Let’s Eat Healthy Award Winners

Retrieved on: 
Tuesday, March 19, 2024
Dairy Council of California, Health, California Department, Associate, California State University, School, Agriculture, University of California, Wellness, College, Foodservice, Management

SACRAMENTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Dairy Council of California, a leader in nutrition education and advocacy, is proud to announce the winners of its fifth annual Let’s Eat Healthy Award.

Key Points: 
  • SACRAMENTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Dairy Council of California, a leader in nutrition education and advocacy, is proud to announce the winners of its fifth annual Let’s Eat Healthy Award.
  • In support of its cause to elevate the health of children and communities through the pursuit of lifelong healthy eating patterns, the Let’s Eat Healthy Initiative is honoring seven California nutrition champions.
  • The impactful efforts of these winners contribute significantly to enhancing nutrition education and promoting access to healthy food across California.
  • “We extend our sincere congratulations to the 2024 Let’s Eat Healthy Award winners and look forward to our continued partnership.”
    To learn more about this year’s Let’s Eat Healthy Award winners, the Let’s Eat Healthy Initiative or how to access free nutrition programs and resources, visit HealthyEating.org .

Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Research, CLD, Refractive surgery, ASCRS, Patient, Telecanthus, ARVO, University, Cataract, Abstract, Eyelid, Detail, Society, University of California, Irritation, Safety, MGD, Pain, Ophthalmic, Pharmaceutical industry

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).

Key Points: 
  • Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
  • This includes new, long-term data at ASCRS of the company’s lead drug candidate, AZR-MD-001, showing improvement in both signs and symptoms in MGD and Contact Lens Discomfort (CLD).
  • “Together, the data set we are presenting at these prestigious conferences show multiple potential patient benefits and mild, transient side effects in a topical medicine, supporting the potential of AZR-MD-001 as an entirely new approach targeting the underlying cause of many ocular surface diseases,” said Marc Gleeson, Chief Executive Officer of Azura.
  • This causes inflammatory ocular surface conditions, ocular surface dryness, pain, irritation, and reduced quality of vision.

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, RASP, Environment, Patient, NDA, University, Quality of life, Clinical trial, Therapy, University of California, Telecanthus, FDA, Food, DSM-IV codes, Pharmaceutical industry

Following discussions with the FDA, Aldeyra intends to initiate a dry eye chamber clinical trial in the first half of 2024.

Key Points: 
  • Following discussions with the FDA, Aldeyra intends to initiate a dry eye chamber clinical trial in the first half of 2024.
  • In the proposed dry eye chamber trial, patients will be administered vehicle (the drug product without the active ingredient) before and during exposure to a dry eye chamber.
  • The design and statistical powering for the proposed trial are derived from four previously completed dry eye chamber clinical trials with reproxalap.
  • ET today, March 28, 2024, to discuss the clinical development plan for resubmission of the new drug application for reproxalap in dry eye disease.

San Diego Angel Conference VI Announces Six Finalists to Compete for Share of Largest Event-Based Angel Fund in U.S.

Retrieved on: 
Monday, March 25, 2024
Professional Services, Consumer, Small Business, Entrepreneur, Start-Up, Finance, Organization, Conference, SDAC, SDSU, UCSD, Brink, JPMorgan Chase, University, Pillsbury Winthrop Shaw Pittman, University of California, Gust, San Diego State University, Financial services

The San Diego Angel Conference at USD has become the largest event-based angel conference in the country , with an active angel investor group of about 90 accredited investors who invest starting at $7,000 each.

Key Points: 
  • The San Diego Angel Conference at USD has become the largest event-based angel conference in the country , with an active angel investor group of about 90 accredited investors who invest starting at $7,000 each.
  • “The San Diego Angel Conference is truly a unique opportunity for both investors and founders to experience the hands-on learning opportunities of the investment decision process,” Executive Director, JPMorgan Startup Banking David Loseke.
  • SDAC partners with 35+ organizations including USD , San Diego State University ( SDSU ), and University of California, San Diego ( UCSD ), to drive deal flow and mentor startups.
  • SDAC Founder Mysty Rusk says, “Over six years, San Diego Angel Conference at USD has focused on activating accredited investors, funding innovative early-stage companies, and supporting solutions that solve real-world problems.

CEO and Public Company Leader JuE Wong (Olaplex Holdings, Elizabeth Arden, Inc.) Joins FireFly Automatix Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Sports, Robotics, Technology, Agriculture, Golf, Agritech, Natural Resources, Environment, Construction & Property, Green Technology, Other Technology, Landscape, Astral, EOY, PepsiCo, CEW, EV, Automatix, Growth, Woman, University, IPO, ANU, WPP plc, University of California, Commerce, AV, Initial public offering, Multimedia, Firefly, UCLA, Australian National University, The Wall Street Journal, Management

FireFly Automatix , Inc., an industry leader in AV and EV professional turfgrass mowing technology, today appointed JuE Wong, a five-time CEO/President with specialized expertise in turn-around and hyper-growth companies, to the company’s Board of Directors.

Key Points: 
  • FireFly Automatix , Inc., an industry leader in AV and EV professional turfgrass mowing technology, today appointed JuE Wong, a five-time CEO/President with specialized expertise in turn-around and hyper-growth companies, to the company’s Board of Directors.
  • On the heels of this technology and market advance, Wong joins FireFly’s Board of Directors in propelling FireFly’s additional expansion through 2024 and beyond.
  • Prior to OLPX, she was the CEO of Moroccanoil Inc., President of Elizabeth Arden Inc., CEO of StriVectin Inc. and CEO of Astral Health and Beauty.
  • “The level of experience and track record of success JuE Wong brings to FireFly is nothing short of phenomenal,” said Andrew Limpert, CEO of FireFly Automatix.